Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 15 (7), 405-14

Type I Interferons in Anticancer Immunity

Affiliations
Review

Type I Interferons in Anticancer Immunity

Laurence Zitvogel et al. Nat Rev Immunol.

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

Similar articles

See all similar articles

Cited by 207 PubMed Central articles

See all "Cited by" articles

References

    1. Oncoimmunology. 2013 May 1;2(5):e24170 - PubMed
    1. Nature. 2007 Dec 6;450(7171):903-7 - PubMed
    1. J Clin Oncol. 2006 Jul 1;24(19):3164-71 - PubMed
    1. Cancer Discov. 2014 Jun;4(6):674-87 - PubMed
    1. Blood. 2011 Oct 13;118(15):4179-87 - PubMed

Publication types

Substances

LinkOut - more resources

Feedback